Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,241
Total Claims
$1.7M
Drug Cost
276
Beneficiaries
$6,050
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 109,535 Physician Assistant providers
+741%
Cost per patient vs peers
$6,050 vs $719 avg
+274%
Brand preference vs peers
24.9% vs 6.7% avg
🔎 Data Overview
Cost per patient is 741% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 2,540 claims · $1.4M
Generic: 7,663 claims · $269K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Diclofenac Sodium | 47 | $187K |
| Lipase/Protease/Amylase | 192 | $154K |
| Lipase/Protease/Amylase | 102 | $122K |
| Apixaban | 131 | $84K |
| Linaclotide | 144 | $80K |
| Dulaglutide | 78 | $80K |
| Dexlansoprazole | 219 | $59K |
| Icosapent Ethyl | 152 | $56K |
| Omeprazole/Sodium Bicarbonate | 20 | $51K |
| Linagliptin | 88 | $49K |
| Sitagliptin Phos/Metformin Hcl | 77 | $48K |
| Diclofenac Sodium | 307 | $45K |
| Rivastigmine | 55 | $41K |
| Vibegron | 64 | $36K |
| Lidocaine | 60 | $36K |
Prescribing Profile
Patient Profile
77
Avg Age
72%
Female
1.56
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data